CARA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.6843 USD | -2.24% |
|
+3.52% | -7.90% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 752 | 754 | 651.1 | 577.1 | 40.48 | 37.41 | - | - |
| Enterprise Value (EV) 1 | 752 | 754 | 484.1 | 431.7 | -60.28 | 27.01 | 66.51 | -60.79 |
| P/E ratio | -6.47 x | 84.1 x | -7 x | -6.75 x | -0.34 x | -0.63 x | -0.67 x | -0.91 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 37.8 x | 5.58 x | 28.3 x | 13.8 x | 1.93 x | 6.69 x | 10.2 x | 9.92 x |
| EV / Revenue | 37.8 x | 5.58 x | 21 x | 10.3 x | -2.87 x | 4.83 x | 18.1 x | -16.1 x |
| EV / EBITDA | -6.75 x | 135 x | -5.45 x | -4.95 x | - | -0.46 x | -1.22 x | 1.25 x |
| EV / FCF | -6.88 x | -129 x | -8.05 x | -5.48 x | - | -0.49 x | -1.68 x | 2.68 x |
| FCF Yield | -14.5% | -0.77% | -12.4% | -18.2% | - | -204% | -59.4% | 37.3% |
| Price to Book | - | - | 2.86 x | 3.64 x | 0.7 x | 3.6 x | -1.63 x | 0.48 x |
| Nbr of stocks (in thousands) | 46,679 | 49,832 | 53,459 | 53,734 | 54,481 | 54,667 | - | - |
| Reference price 2 | 16.11 | 15.13 | 12.18 | 10.74 | 0.7430 | 0.6843 | 0.6843 | 0.6843 |
| Announcement Date | 2/27/20 | 2/25/21 | 3/1/22 | 3/6/23 | 3/4/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 19.89 | 135.1 | 23.03 | 41.87 | 20.97 | 5.589 | 3.669 | 3.772 |
| EBITDA 1 | -111.5 | 5.594 | -88.84 | -87.29 | - | -58.29 | -54.52 | -48.56 |
| EBIT 1 | -111.7 | 5.385 | -89.08 | -87.54 | -121.5 | -64 | -66.23 | -62.66 |
| Operating Margin | -561.6% | 3.99% | -386.85% | -209.08% | -579.43% | -1,145.25% | -1,804.87% | -1,661.37% |
| Earnings before Tax (EBT) 1 | -107.2 | 7.719 | -88.44 | -85.47 | -118.5 | -63.57 | -66.91 | -62.41 |
| Net income 1 | -106.4 | 8.41 | -88.44 | -85.47 | -118.5 | -63.57 | -66.91 | -62.41 |
| Net margin | -534.91% | 6.23% | -384.06% | -204.16% | -565.21% | -1,137.54% | -1,823.46% | -1,654.59% |
| EPS 2 | -2.490 | 0.1800 | -1.740 | -1.590 | -2.190 | -1.088 | -1.018 | -0.7525 |
| Free Cash Flow 1 | -109.2 | -5.836 | -60.13 | -78.77 | - | -55.2 | -39.5 | -22.7 |
| FCF margin | -549.35% | -4.32% | -261.1% | -188.15% | - | -987.73% | -1,076.47% | -601.83% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 2/27/20 | 2/25/21 | 3/1/22 | 3/6/23 | 3/4/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 20.27 | 0.821 | 4.79 | 23 | 10.81 | 3.261 | 6.165 | 6.933 | 4.866 | 3.004 | 1.69 | 1.443 | 1.343 | 1.113 | 1.2 |
| EBITDA 1 | -1.062 | -33.46 | -27.85 | -4.409 | -23.78 | -31.25 | -27.59 | -32.28 | -28.84 | - | -22.18 | -12.95 | -11.71 | -11.45 | - |
| EBIT 1 | -1.124 | -33.52 | -27.91 | -4.472 | -23.84 | -31.31 | -27.65 | -32.34 | -28.9 | -32.61 | -21.58 | -13.56 | -12.56 | -13.75 | -16.5 |
| Operating Margin | -5.54% | -4,083.07% | -582.69% | -19.44% | -220.52% | -960.04% | -448.5% | -466.46% | -593.88% | -1,085.45% | -1,276.98% | -939.77% | -935.34% | -1,235.6% | -1,375% |
| Earnings before Tax (EBT) 1 | -1.013 | -33.38 | -27.75 | -4.206 | -23.18 | -30.34 | -26.66 | -31.48 | -28.03 | -32.34 | -21.59 | -13.9 | -13.28 | -14.82 | -16.2 |
| Net income 1 | -1.013 | -33.38 | -27.75 | -4.206 | -23.18 | -30.34 | -26.66 | -31.48 | -28.03 | -32.34 | -21.59 | -13.9 | -13.28 | -14.82 | -16.2 |
| Net margin | -5% | -4,066.02% | -579.31% | -18.28% | -214.37% | -930.36% | -432.52% | -454.05% | -576.08% | -1,076.46% | -1,277.74% | -963.46% | -989.07% | -1,331.48% | -1,350% |
| EPS 2 | -0.0200 | -0.6300 | -0.5200 | -0.0800 | -0.4300 | -0.5600 | -0.4900 | -0.5800 | -0.5200 | -0.5900 | -0.3925 | -0.2525 | -0.2225 | -0.2400 | -0.2900 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/8/21 | 3/1/22 | 5/9/22 | 8/8/22 | 11/7/22 | 3/6/23 | 5/15/23 | 8/7/23 | 11/13/23 | 3/4/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | 29.1 | - |
| Net Cash position 1 | - | - | 167 | 145 | 101 | 10.4 | - | 98.2 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | -0.5337 x | - |
| Free Cash Flow 1 | -109 | -5.84 | -60.1 | -78.8 | - | -55.2 | -39.5 | -22.7 |
| ROE (net income / shareholders' equity) | -66.4% | 3.86% | -37.1% | -44.3% | -110% | -185% | - | -103% |
| ROA (Net income/ Total Assets) | - | - | -34.1% | -39.8% | - | - | - | - |
| Assets 1 | - | - | 259.1 | 214.6 | - | - | - | - |
| Book Value Per Share 2 | - | - | 4.250 | 2.950 | 1.050 | 0.1900 | -0.4200 | 1.440 |
| Cash Flow per Share 2 | - | -0.1200 | - | -1.470 | - | -0.9700 | -0.6600 | -0.2900 |
| Capex 1 | 0.02 | 0.35 | 0.04 | 0.04 | - | 1.65 | 1.65 | 1.65 |
| Capex / Sales | 0.09% | 0.26% | 0.17% | 0.1% | - | 29.52% | 44.97% | 43.75% |
| Announcement Date | 2/27/20 | 2/25/21 | 3/1/22 | 3/6/23 | 3/4/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
0.6843
USD
Average target price
5.12
USD
Spread / Average Target
+648.21%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -7.90% | 37.41M | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| -9.14% | 11.95B | |
| +5.24% | 8.71B | |
| -8.42% | 8.12B |
- Stock Market
- Equities
- CARA Stock
- Financials Cara Therapeutics, Inc.
